Abstract
Both short and long sleep are associated with an adverse lipid profile, likely through different biological pathways. To elucidate the biology of sleep-associated adverse lipid profile, we conduct multi-ancestry genome-wide sleep-SNP interaction analyses on three lipid traits (HDL-c, LDL-c and triglycerides). In the total study sample (discovery + replication) of 126,926 individuals from 5 different ancestry groups, when considering either long or short total sleep time interactions in joint analyses, we identify 49 previously unreported lipid loci, and 10 additional previously unreported lipid loci in a restricted sample of European-ancestry cohorts. In addition, we identify new gene-sleep interactions for known lipid loci such as LPL and PCSK9. The previously unreported lipid loci have a modest explained variance in lipid levels: most notable, gene-short-sleep interactions explain 4.25% of the variance in triglyceride level. Collectively, these findings contribute to our understanding of the biological mechanisms involved in sleep-associated adverse lipid profiles.
| Original language | English |
|---|---|
| Article number | 5121 |
| Journal | Nature Communications |
| Volume | 10 |
| Issue number | 1 |
| DOIs | |
| State | Published - Dec 1 2019 |
Bibliographical note
Publisher Copyright:© 2019, The Author(s).
Funding
D.O.M.K. is a part-time research consultant for Metabolon, Inc. H.J.G. has received travel grants and speakers honoraria from Fresenius Medical Care, Neuraxpharm and Janssen Cilag. H.J.G. has received research funding from the German Research Foundation (DFG), the German Ministry of Education and Research (BMBF), the DAMP Foundation, Fresenius Medical Care, the EU “Joint Programme Neurodegenerative Disorders (JPND) and the European Social Fund (ESF)”. S.A. reports employment and stock options with 23andMe, Inc. This project was supported by a grant from the US National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (R01HL118305). This research was supported in part by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. Tuomas O. Kilpeläinen was supported by the Danish Council for Independent Research (DFF–6110-00183) and the Novo Nordisk Foundation (NNF18CC0034900, NNF17OC0026848 and NNF15CC0018486). Diana van Heemst was supported by the European Commission funded project HUMAN (Health-2013-INNOVATION-1-602757). Susan Redline was supported in part by NIH R35HL135818 and HL11338. Study-specific acknowledgements can be found in the Supplementary Notes 2 and 4. The data on coronary artery disease have been contributed by the Myocardial Infarction Genetics and CARDIoGRAM investigators, and have been downloaded from www.CARDIOGRAMPLUSC4D.ORG.
| Funders | Funder number |
|---|---|
| National Institutes of Health (NIH) | R35HL135818, HL11338, R01HL118305 |
| National Institutes of Health (NIH) | |
| National Heart, Lung, and Blood Institute (NHLBI) | R21HL140385 |
| National Heart, Lung, and Blood Institute (NHLBI) | |
| National Human Genome Research Institute | |
| EU Joint Programme – Neurodegenerative Disease Research | |
| Fresenius Medical Care North America | |
| European Commission | Health-2013-INNOVATION-1-602757 |
| European Commission | |
| Deutsche Forschungsgemeinschaft | |
| Bundesministerium für Bildung und Forschung | |
| Danmarks Frie Forskningsfond | DFF–6110-00183 |
| Danmarks Frie Forskningsfond | |
| European Social Fund-ESF | |
| Novo Nordisk Fonden | NNF17OC0026848, NNF15CC0018486, NNF18CC0034900 |
| Novo Nordisk Fonden | |
| Damp Stiftung |
ASJC Scopus subject areas
- General Chemistry
- General Biochemistry, Genetics and Molecular Biology
- General Physics and Astronomy